| Clinical development is undergoing a structural shift. Protocols are growing more complex, budgets are shrinking, and ...
Experts at SCOPE Europe 2025 confronted the challenges posed by rapid trial proliferation, digital transformation and ...
Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug ...
Acknowledging China's innovative biotech environment, UK-headquartered pharmaceutical company AstraZeneca said it is ...
NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class pharmacology ...
Incyte (($INCY)) announced an update on their ongoing clinical study. Incyte Corporation is currently conducting a clinical study titled ‘An ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback